STOCK TITAN

AIBiotics Therapies issues Q3 going-concern warning

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

AIBiotics Therapies reported no revenue for the quarter ended September 30, 2026; nine-month revenue was $0 versus $2,183 in 2025. Net loss was $282,413 for the quarter and $1,237,486 for nine months, versus $529,921 and $1,607,467, respectively, in 2025. At quarter-end, cash was $223,074 and the working capital deficit was $4,906,285; operations used $93,633 of cash.

Management said substantial doubt exists about the company’s ability to continue as a going concern within one year after the statements are issued. At September 30, 2026, current liabilities were $5,171,551 against current assets of $265,266. Management said operations depend on additional financing and gave no assurance of success. Disclosure controls were ineffective because of a material weakness.

After quarter-end, NovaCore acquired PlayJamaica assets for 22,500 Series B Preferred shares with aggregate stated value of $225,000; the seller may earn up to $3,000,000 more on revenue milestones. A proposed Empulser purchase remained unclosed; consideration is Series C Preferred Stock with aggregate stated value of $22,000,000, 10% to be released at closing and the remainder upon patent, product and revenue milestones within 36 months after closing. On October 29, 2026, AIBiotics issued 10,000,000 shares to director Mark Croskery and 100,000,000 to CEO Ben Kaplan for accrued fees.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 3 points

How the balance works

Positive

  • Moderate pointNine-month net loss declined to $1,237,486, from $1,607,467 in 2025.
  • Moderate pointNet cash used in operating activities declined to $93,633, from $371,636 in 2025.

Negative

  • Major pointSubstantial doubt about continuing as a going concern was raised within one year after the statements are issued.
  • Major pointDisclosure controls were ineffective due to a material weakness as of September 30, 2026.
  • Minor pointNine-month revenue fell to $0, from $2,183 in 2025.
Quarterly net loss $282,413 Three months ended September 30, 2026; $529,921 for the same period in 2025.
Nine-month net loss $1,237,486 Nine months ended September 30, 2026; $1,607,467 in 2025.
Nine-month revenue $0 Nine months ended September 30, 2026; $2,183 in 2025.
Cash $223,074 As of September 30, 2026; $255,940 as of December 31, 2025.
Net cash used in operating activities $93,633 Nine months ended September 30, 2026; $371,636 in 2025.
Working capital deficit $4,906,285 As of September 30, 2026; $4,564,798 as of December 31, 2025.
PlayJamaica asset consideration $225,000 aggregate stated value Consideration for 22,500 Series B Preferred Stock shares issued through NovaCore on October 12, 2026.
Empulser proposed consideration $22,000,000 aggregate stated value Proposed exchange for Series C Preferred Stock; the agreement had not closed as of the report date.
going concern financial
"prepared on a going concern basis"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
working capital deficit financial
"working capital deficit of $4,906,285"
A working capital deficit occurs when a company's short-term obligations—like bills, supplier payments and near-term debt—are larger than its readily available short-term resources such as cash, money expected from customers, and inventory that can be sold. Like a household whose monthly bills exceed its checking account, it signals potential difficulty paying immediate expenses, which matters to investors because it raises the chance the company will need outside financing or cut operations, affecting risk and value.
material weakness technical
"a material weakness in our internal control over financial reporting"
A material weakness is a significant flaw in the systems and checks a company uses to ensure its financial reports are accurate, meaning errors or fraud could happen and not be caught. For investors it matters because it raises the risk that reported results are unreliable—similar to finding a hole in a ship’s hull—potentially leading to corrected financials, regulatory action, reduced trust, and negative effects on stock value and borrowing costs.
original issue discount financial
"original issue discount of $18,750"
Original issue discount (OID) is the difference between a debt security’s face value and the lower price at which it is first sold, treated as additional interest that accrues over the life of the instrument. For investors it matters because OID raises the effective yield and changes taxable income and the holding’s cost basis over time — think of buying a $100 voucher for $90 and recognizing the $10 gain as earned interest as the voucher approaches maturity.
mezzanine equity financial
"recorded as mezzanine equity in accordance with ASC 480"
Mezzanine equity is a layer of financing that sits between bank loans and full ownership, combining elements of borrowed money and equity. It often gives lenders higher potential returns in exchange for taking more risk, sometimes with the option to convert into ownership or receive extra payments; think of it as a middle seat that pays more because it’s less secure than front-row debt. Investors watch it because it affects a company’s debt risk, potential dilution of ownership, and expected returns.
reverse merger technical
"accounted for as a reverse merger"
A reverse merger is when a private company becomes publicly traded by combining with an already listed public shell company, allowing the private business to gain a stock market listing without going through a traditional IPO. Investors care because this shortcut can be faster and cheaper than an IPO but often comes with less regulatory vetting and market visibility, so it can mean higher uncertainty about valuation, financial transparency, and future liquidity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was AIBT’s net loss in the third quarter of 2026?

AIBiotics Therapies reported a net loss of $282,413 for the three months ended September 30, 2026, compared with $529,921 for the same period in 2025.

Why did AIBT disclose substantial doubt about continuing as a going concern?

The company cited a $4,906,285 working capital deficit at September 30, 2026, with $265,266 in current assets and $5,171,551 in current liabilities. It also reported a nine-month net loss of $1,237,486 and $93,633 of cash used in operating activities; management said these conditions raised substantial doubt within one year after issuance.

What assets did AIBT acquire from PlayJamaica, and what additional consideration is possible?

Through NovaCore, AIBiotics acquired software, trademarks, assigned contracts and customer data for 22,500 Series B Preferred Stock shares with aggregate stated value of $225,000. The seller may earn up to $3,000,000 more in Series B Preferred Stock against cumulative gross revenue milestones of $500,000, $1,500,000, $3,000,000 and $5,000,000 during the four years after closing.

Has AIBT’s proposed Empulser acquisition closed, and how is consideration structured?

The agreement had not closed as of the report date. It provides for Series C Preferred Stock with aggregate stated value of $22,000,000; 10% of the consideration is to be released at closing and the remainder upon specified patent, product and revenue milestones within 36 months after closing. Any consideration not earned is canceled.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001763329 --12-31 AIBOTICS THERAPIES, INC. false 2026 Q3 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 0001763329 2026-01-01 2026-09-30 0001763329 2026-09-30 0001763329 2025-06-30 0001763329 2026-11-20 0001763329 2025-12-31 0001763329 us-gaap:SeriesBPreferredStockMember 2026-09-30 0001763329 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001763329 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001763329 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001763329 2026-07-01 2026-09-30 0001763329 2025-07-01 2025-09-30 0001763329 2025-01-01 2025-09-30 0001763329 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001763329 2024-12-31 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2024-12-31 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2024-12-31 0001763329 us-gaap:CommonStockMember 2024-12-31 0001763329 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001763329 us-gaap:RetainedEarningsMember 2024-12-31 0001763329 2025-01-01 2025-03-31 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001763329 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001763329 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001763329 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001763329 2025-03-31 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2025-03-31 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2025-03-31 0001763329 us-gaap:CommonStockMember 2025-03-31 0001763329 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001763329 us-gaap:RetainedEarningsMember 2025-03-31 0001763329 2025-04-01 2025-06-30 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001763329 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001763329 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001763329 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2025-06-30 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2025-06-30 0001763329 us-gaap:CommonStockMember 2025-06-30 0001763329 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001763329 us-gaap:RetainedEarningsMember 2025-06-30 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001763329 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001763329 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001763329 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001763329 2025-09-30 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2025-09-30 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2025-09-30 0001763329 us-gaap:CommonStockMember 2025-09-30 0001763329 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001763329 us-gaap:RetainedEarningsMember 2025-09-30 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2025-12-31 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2025-12-31 0001763329 us-gaap:CommonStockMember 2025-12-31 0001763329 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001763329 us-gaap:RetainedEarningsMember 2025-12-31 0001763329 2026-01-01 2026-03-31 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001763329 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001763329 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001763329 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001763329 2026-03-31 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2026-03-31 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2026-03-31 0001763329 us-gaap:CommonStockMember 2026-03-31 0001763329 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001763329 us-gaap:RetainedEarningsMember 2026-03-31 0001763329 2026-04-01 2026-06-30 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001763329 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001763329 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001763329 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001763329 2026-06-30 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2026-06-30 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2026-06-30 0001763329 us-gaap:CommonStockMember 2026-06-30 0001763329 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001763329 us-gaap:RetainedEarningsMember 2026-06-30 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001763329 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001763329 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001763329 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001763329 us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember 2026-09-30 0001763329 us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember 2026-09-30 0001763329 us-gaap:CommonStockMember 2026-09-30 0001763329 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001763329 us-gaap:RetainedEarningsMember 2026-09-30 0001763329 us-gaap:EquipmentMember 2026-09-30 0001763329 us-gaap:IntellectualPropertyMember 2026-09-30 0001763329 fil:ConvertibleDebt1Member 2026-01-01 2026-09-30 0001763329 fil:ConvertibleDebt1Member 2025-01-01 2025-09-30 0001763329 us-gaap:IntellectualPropertyMember 2025-12-31 0001763329 fil:MajorShareholderMember 2026-01-01 2026-09-30 0001763329 fil:MajorShareholderMember 2025-01-01 2025-09-30 0001763329 fil:MajorShareholderMember 2026-09-30 0001763329 fil:BoardCompensationMember 2026-09-30 0001763329 fil:BoardCompensationMember 2025-12-31 0001763329 fil:LenderAMember 2026-01-01 2026-09-30 0001763329 fil:LenderGFormerlyLenderAMember 2025-04-22 2025-04-22 0001763329 fil:LenderGFormerlyLenderAMember 2025-01-01 2025-12-31 0001763329 fil:LenderGMember 2026-04-30 2026-04-30 0001763329 fil:LenderGFormerlyLenderAMember 2026-04-01 2026-06-30 0001763329 fil:LenderGFormerlyLenderAMember 2026-07-01 2026-09-30 0001763329 fil:LenderGFormerlyLenderAMember 2026-09-30 0001763329 fil:LenderBMember 2021-01-01 2021-12-31 0001763329 fil:LenderCMember 2021-01-01 2021-12-31 0001763329 fil:LenderEMember 2022-01-01 2022-12-31 0001763329 fil:LenderFMember 2024-01-01 2024-12-31 0001763329 fil:LenderGMember 2025-01-01 2025-09-30 0001763329 fil:LenderHMember 2025-01-01 2025-09-30 0001763329 fil:LenderGMember 2026-01-01 2026-09-30 0001763329 fil:LenderHMember 2026-01-01 2026-09-30 0001763329 fil:LenderIMember 2026-01-01 2026-09-30 0001763329 fil:LenderGFormerlyLenderAMember 2026-01-01 2026-09-30 0001763329 fil:LenderGFormerlyLenderAMember 2025-12-31 0001763329 fil:LenderBMember 2026-01-01 2026-09-30 0001763329 fil:LenderBMember 2026-09-30 0001763329 fil:LenderBMember 2025-12-31 0001763329 fil:LenderDMember 2026-01-01 2026-09-30 0001763329 fil:LenderDMember 2026-09-30 0001763329 fil:LenderDMember 2025-12-31 0001763329 fil:LenderEMember 2026-01-01 2026-09-30 0001763329 fil:LenderEMember 2026-09-30 0001763329 fil:LenderEMember 2025-12-31 0001763329 fil:LenderFMember 2026-01-01 2026-09-30 0001763329 fil:LenderFMember 2026-09-30 0001763329 fil:LenderFMember 2025-12-31 0001763329 fil:LenderGMember 2026-09-30 0001763329 fil:LenderGMember 2025-12-31 0001763329 fil:LenderHMember 2026-09-30 0001763329 fil:LenderHMember 2025-12-31 0001763329 fil:LenderIMember 2026-09-30 0001763329 fil:LenderIMember 2025-12-31 0001763329 2024-06-23 0001763329 2024-06-24 0001763329 fil:StockIssuance8Memberus-gaap:CommonStockMember 2025-01-01 2025-12-31 0001763329 fil:StockIssuance8Member 2025-01-01 2025-12-31 0001763329 2025-01-01 2025-12-31 0001763329 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001763329 fil:MayConsultingAgreementMember 2025-01-01 2025-09-30 0001763329 2022-12-31 0001763329 2022-01-01 2022-12-31 0001763329 2023-03-31 0001763329 2023-12-31

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 10-Q

 

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the quarterly period ended September 30, 2026

 

Or

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the transition period from _______ to _____

 

 

Commission file number:  000-56022

 

AIBiotics Therapies, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

 

87-0645794

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

 

 

100 SE 2nd Street, Suite 2000, Miami, FL 33131

(Address of principal executive offices, including zip code)

 

954-233-3511

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

N/A

N/A

N/A

 

Securities registered pursuant to Section 12(g) of the Act:

 

Common Stock, Par Value $0.001

(Title of class)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  ¨ Yes  x No

 

Indicate by check mark if the registrant is not required to file reports pursuant to the Section 13 or Section 15(d) of the Exchange Act. ¨ Yes  x No

 



 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x Yes  ¨ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨

 

Accelerated filer ¨

 

Non-accelerated Filer x

 

Smaller reporting company ☒

 

Emerging growth company ☐

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  No

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  ☐Yes xNo

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. As of November 20, 2026, we had 1,000,165,334 shares of common stock outstanding.

 



AIBiotics Therapies, Inc.

Form 10-Q for the Quarter Ended September 30, 2026 

 

TABLE OF CONTENTS

 

Item

 

Page

 

Part I—Financial Information

 

 

 

 

1

Financial Statements

4

 

Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and December 31, 2025

4

 

Condensed Consolidated Statements of Operations for the Three and Nine months Ended September 30, 2026 and 2025 (unaudited)

5

 

Condensed Consolidated Statements of Mezzanine Equity and Stockholders’ Deficit for the Three and Nine months Ended September 30, 2026 and 2025 (unaudited)

6

 

Condensed Consolidated Statements of Cash Flows for the Nine months Ended September 30, 2026 and 2025 (unaudited)

7

 

Notes to the Unaudited Condensed Consolidated Financial Statements

8

2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

18

3

Quantitative and Qualitative Disclosures about Market Risk

21

4

Controls and Procedures

21

 

 

 

 

Part II—Other Information

 

 

 

 

6

Exhibits

22

 

Signatures

23



PART I–FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

AIBIOTICS THERAPIES, INC

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF SEPTEMBER 30, 2026 (UNAUDITED) AND DECEMBER 31, 2025

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

 

 

(unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

 

 

Cash

 

$

 223,074

 

 

$

 255,940

 

Prepaid expenses

 

 

 1,667

 

 

 

 14,167

 

Inventory

 

 

 40,525

 

 

 

 -

 

Total Current Assets

 

 

 265,266

 

 

 

 270,107

 

 

 

 

 

 

 

 

 

 

NON-CURRENT ASSETS:

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

 -

 

 

 

 -

 

Intangible assets, net

 

 

 105,936

 

 

 

 604,566

 

TOTAL ASSETS

 

$

 371,202

 

 

$

 874,673

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

 653,039

 

 

$

 532,302

 

Accrued expenses – related party

 

 

 1,023,000

 

 

 

 807,000

 

Accrued interest

 

 

 308,994

 

 

 

 216,734

 

Convertible note payable, net of debt discount

 

 

 1,025,918

 

 

 

 1,118,269

 

Notes payable – related party

 

 

 165,000

 

 

 

 165,000

 

Shares to be issued

 

 

 1,995,600

 

 

 

 1,995,600

 

TOTAL LIABILITIES

 

 

 5,171,551

 

 

 

 4,834,905

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies (Note 9 – Commitments and Contingencies)

 

 

 -

 

 

 

 -

 

 

 

 

 

 

 

 

 

 

MEZZANINE EQUITY

 

 

 

 

 

 

 

 

Series B Preferred stock, $0.001 par value; 1,500,000 shares authorized at September 30, 2026 and December 31, 2025; 200,000 shares issued and outstanding as of September 30, 2026 and December 31, 2025; liquidation preference of $0 as of September 30, 2026 and December 31, 2025

 

 

 200

 

 

 

 200

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS’ DEFICIT

 

 

 

 

 

 

 

 

Preferred stock, 5,000,000 shares authorized:

 

 

 

 

 

 

 

 

Series A Preferred Stock, $0.001 par value, 1 share authorized and 0 shares outstanding at September 30, 2026 and December 31, 2025

 

 

 -

 

 

 

 -

 

Common stock, $0.001 par value; 7,500,000,000 shares authorized at September 30, 2026 and December 31, 2025; 890,165,334 and 486,895,359 shares issued and outstanding as of September 30, 2026, and December 31, 2025, respectively

 

 

 890,165

 

 

 

 486,895

 

Additional paid in capital

 

 

 8,571,779

 

 

 

 8,577,680

 

Accumulated deficit

 

 

 (14,262,493

)

 

 

 (13,025,007

)

TOTAL STOCKHOLDERS’ DEFICIT

 

 

 (4,800,349

)

 

 

 (3,960,232

)

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT

 

$

 371,202

 

 

$

 874,673

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


4


AIBIOTICS THERAPIES, INC

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

For the Three Months Ended

 

For the Nine months Ended

 

September 30,

 

September 30,

2026

 

2025

 

2026

 

2025

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

$

- 

 

$

- 

 

$

 - 

 

$

2,183 

GROSS PROFIT

 

- 

 

 

- 

 

 

 - 

 

 

2,183 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSE

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

301,327 

 

 

480,364 

 

 

 1,074,453 

 

 

1,372,590 

TOTAL OPERATING EXPENSES

 

301,327 

 

 

480,364 

 

 

 1,074,453 

 

 

1,372,590 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS FROM OPERATIONS

 

(301,327)

 

 

(480,364)

 

 

 (1,074,453)

 

 

(1,370,407)

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME (EXPENSE)

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

(42,839)

 

 

(11,154)

 

 

 (148,398)

 

 

(166,347)

Gain (loss) on extinguishment of liabilities

 

61,753 

 

 

(38,403)

 

 

 (14,635)

 

 

(70,713)

TOTAL OTHER INCOME (EXPENSE)

 

18,914 

 

 

(49,557)

 

 

 (163,033)

 

 

(237,060)

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS BEFORE PROVISION FOR INCOME TAXES

 

(282,413)

 

 

(529,921)

 

 

 (1,237,486)

 

 

(1,607,467)

Provision for income taxes

 

- 

 

 

- 

 

 

 - 

 

 

- 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS

$

(282,413)

 

$

(529,921)

 

$

 (1,237,486)

 

$

(1,607,467)

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS PER SHARE – BASIC AND DILUTED

$

(0.00)

 

$

(0.00)

 

$

 (0.00)

 

$

(0.02)

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING – BASIC AND DILUTED

 

847,617,086 

 

 

195,466,263 

 

 

 679,842,123 

 

 

97,211,226 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


5


 

AIBIOTICS THERAPIES, INC.

 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT

 

 

 

Series B

 

 

Series A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred Shares

 

 

Preferred Stock

 

Common Stock

 

Additional

 

Accumulated

 

 

Total

 

Shares

 

Amount

 

 

Shares

 

Amount

 

Shares

 

Amount

 

Paid-In Capital

 

Deficit

 

 

Stockholders’ Deficit

Balance as of December 31, 2024

 

200,000

 

$

200

 

 

-

 

$

-

 

39,990,903

 

$

39,991

 

$

7,374,297

 

$

(10,809,256)

 

$

(3,394,768)

Common stock issued to settle accounts payable and accrued expenses

 

-

 

 

-

 

 

-

 

 

-

 

5,253,234

 

 

5,253

 

 

143,941

 

 

-

 

 

149,194

Net loss for the three months ended, March 31, 2025

 

-

 

 

-

 

 

-

 

 

-

 

-

 

 

-

 

 

-

 

 

(591,397)

 

 

(591,397)

Balance as of March 31, 2025

 

200,000

 

$

200

 

 

-

 

$

-

 

45,244,137

 

$

45,244

 

$

7,518,238

 

$

(11,400,653)

 

$

(3,836,971)

Common stock issued to settle accounts payable and accrued expenses

 

-

 

 

-

 

 

-

 

 

-

 

6,380,952

 

 

6,381

 

 

108,429

 

 

-

 

 

114,810

Net loss for the three months ended, June 30, 2025

 

-

 

 

-

 

 

-

 

 

-

 

-

 

 

-

 

 

-

 

 

(486,149)

 

 

(486,149)

Balance as of June 30, 2025

 

200,000

 

$

200

 

 

-

 

$

-

 

51,625,089

 

$

51,625

 

$

7,626,667

 

$

(11,886,802)

 

$

(4,208,310)

Common stock issued to settle accounts payable and accrued expenses

 

-

 

 

-

 

 

-

 

 

-

 

29,669,748

 

 

29,670

 

 

85,837

 

 

-

 

 

115,507

Common stock issued to settle accrued expenses - related party

 

-

 

 

-

 

 

-

 

 

-

 

75,000,000

 

 

75,000

 

 

150,000

 

 

-

 

 

225,000

Common stock issued to settle accrued interest

 

-

 

 

-

 

 

-

 

 

-

 

38,971,457

 

 

38,971

 

 

102,251

 

 

-

 

 

141,222

Common stock issued for cash and settlement of accrued interest, net of issuance costs

 

 

 

 

 

 

 

 

 

 

 

 

106,957,599

 

 

106,958

 

 

213,915

 

 

-

 

 

320,873

Issuance of shares of common stock, net of issuance costs

 

-

 

 

-

 

 

-

 

 

-

 

16,666,666

 

 

16,666

 

 

33,334

 

 

-

 

 

50,000

Net loss for the quarter ended, September 30, 2025

 

-

 

 

-

 

 

-

 

 

-

 

-

 

 

-

 

 

-

 

 

(529,921)

 

 

(529,921)

Balance as of September 30, 2025

 

200,000

 

$

200

 

 

-

 

$

-

 

318,890,559

 

$

318,890

 

$

8,212,004

 

$

(12,416,723)

 

$

(3,885,629)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Series B

 

 

Series A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred Shares

 

 

Preferred Stock

 

Common Stock

 

 

Additional

 

 

Accumulated

 

 

Total

 

 

Shares

 

 

Amount

 

 

Shares

 

Amount

 

Shares

 

Amount

 

 

Paid-In Capital

 

 

Deficit

 

 

Stockholders’ Deficit

Balance as of December 31, 2025

 

200,000

 

$

200

 

 

-

 

$

-

#

486,895,359

 

$

486,895

 

$

8,577,680

 

$

(13,025,007)

 

$

(3,960,232)

Common stock issued to settle accounts payable and accrued expenses

 

-

 

 

-

 

 

-

 

 

-

 

26,900,000

 

 

26,900

 

 

(5,380)

 

 

-

 

 

21,520

Shares issued for cash, settlement of accounts payable and accrued expenses, and third-party costs

 

-

 

 

-

 

 

-

 

 

-

 

25,572,128

 

 

25,572

 

 

51,144

 

 

-

 

 

76,716

Net loss for the three months ended, March 31, 2026

 

-

 

 

-

 

 

-

 

 

-

 

-

 

 

-

 

 

-

 

 

(418,105)

 

 

(418,105)

Balance as of March 31, 2026

 

200,000

 

$

200

 

 

-

 

$

-

 

539,367,487

 

$

539,367

 

$

8,623,444

 

$

(13,443,112)

 

$

(4,280,101)

Shares issued for conversion of convertible notes and settlement of accounts payable, accrued expenses and services

 

-

 

 

-

 

 

-

 

 

-

 

183,139,147

 

 

183,139

 

 

32,028

 

 

-

 

 

215,167

Net loss for the three months ended, June 30, 2026

 

-

 

 

-

 

 

-

 

 

-

 

-

 

 

-

 

 

-

 

 

(536,968)

 

 

(536,968)

Balance as of June 30, 2026

 

200,000

 

 

200

 

 

-

 

 

-

 

722,506,634

 

 

722,506

 

 

8,655,472

 

 

(13,980,080)

 

 

(4,601,902)

Shares issued for conversion of convertible notes and settlement of accounts payable, accrued expenses and services

 

-

 

 

-

 

 

-

 

 

-

 

167,658,700

 

 

167,659

 

 

(83,693)

 

 

-

 

 

83,966

Net loss for the three months ended September 30, 2026

 

-

 

 

-

 

 

-

 

 

-

 

-

 

 

-

 

 

-

 

 

(282,413)

 

 

(282,413)

Balance as of September 30, 2026

 

200,000

 

 

200

 

 

-

 

 

-

 

890,165,334

 

 

890,165

 

 

8,571,779

 

 

(14,262,493)

 

 

(4,800,349)

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


6


 

AIBOTICS THERAPIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (UNAUDITED)

 

 

For the Nine months Ended September 30,

2026

 

2025

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

Net loss

$

(1,237,486)

 

$

(1,607,467)

Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:

 

 

 

 

 

Depreciation expense

 

-

 

 

-

Amortization expense

 

498,630

 

 

496,351

Amortization of debt discount

 

16,541

 

 

5,034

Issuance of common stock for services

 

50,000

 

 

-

Loss on extinguishment of liabilities

 

14,635

 

 

70,713

Changes in operating assets and liabilities:

 

 

 

 

 

Decrease in prepaid expenses

 

12,500

 

 

-

Increase in inventory

 

(40,525)

 

 

-

Increase in accounts payable and accrued expenses

 

266,059

 

 

484,935

Increase in accrued interest

 

110,013

 

 

52,798

Increase in accrued expenses – related party

 

216,000

 

 

126,000

Net cash used in operating activities

 

(93,633)

 

 

(371,636)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

Proceeds from convertible note payable

 

98,000

 

 

250,000

Repayments of convertible note payable

 

(37,233)

 

 

-

Proceeds from the issuance of common stock

 

-

 

 

167,009

Net cash provided by financing activities

 

60,767

 

 

417,009

Net change in cash

 

(32,866)

 

 

45,373

Cash, beginning of period

 

255,940

 

 

185,097

Cash, end of period

$

223,074

 

$

230,470

Supplemental cash flow information:

 

 

 

 

 

Cash paid for interest

$

-

 

$

-

Cash paid for income taxes

$

-

 

$

-

Supplemental Disclosure of Non-Cash Financing Activities:

 

 

 

 

 

Common stock issued to settle accounts payable and accrued expenses

$

21,520

 

$

330,431

Common stock issued to settle accrued expenses - related party

$

-

 

$

225,000

Common stock issued to settle accrued interest

$

-

 

$

323,453

Common stock issued for cash and settlement of accrued interest, net of issuance costs

$

76,716

 

$

-

Shares issued for conversion of convertible notes and settlement of accounts payable, accrued expenses and services

$

234,498

 

$

-

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


7



AIBIOTICS THERAPIES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026 and 2025

 

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Organization and Business Activity

 

The Company was incorporated in Nevada on January 21, 2000, under the name RM Investors, Inc. In December 2020, we entered into definitive agreements with Ehave, Inc., an Ontario corporation (“Ehave”), AIBiotics Therapies Inc., a Florida corporation and wholly owned subsidiary of Ehave (“MYC”), and the former and current directors of 20/20 Global that provide for: (i) 20/20 Global’s purchase for $350,000 in cash of all of the outstanding stock of MYC from Ehave under a Stock Purchase Agreement, resulting in MYC becoming a wholly owned subsidiary of 20/20 Global; and (ii) the change of control of 20/20 Global’s board of directors and management under a Change of Control and Funding Agreement. In a related transaction, Ehave agreed to purchase 9,793,754 shares of 20/20 Global common stock, which constitute approximately 75.77% of the then-issued and outstanding shares of 20/20 Global’s common stock, for $350,000 in cash through a Stock Purchase Agreement (“MYC SPA”) with 20/20 Global stockholders Mark D. Williams, Colin Gibson, and The Robert and Joanna Williams Trust. As of September 30, 2026 Ehave’s ownership has since been diluted to 1.4%.

 

On January 19, 2021, the above transaction closed. Because the former shareholder of AIBiotics Therapies, Inc. acquired 75.77% of the Company’s then-outstanding stock and there was a change in control of the board of directors, the transaction was accounted for as a reverse merger in which AIBiotics Therapies, Inc. was deemed to be the accounting acquirer and the Company the legal acquirer. Subsequent to the transaction, the Company changed its name from 20/20 Global, Inc. to AIBiotics Therapies, Inc.

 

As a result of the transaction, the historical consolidated financial statements of the Company for periods prior to the date of the transaction are those of AIBiotics Therapies, Inc., as the accounting acquirer, and all references to the consolidated financial statements of the Company apply to the historical financial statements of AIBiotics Therapies, Inc. prior to the transaction and the consolidated financial statements of the Company subsequent to the transaction.

 

On November 17, 2024, the Company created a new Florida-based subsidiary, NPD Genius, LLC (“NPD”).  

 

On February 3, 2025, Mycotopia Therapies, Inc. amended its articles of incorporation to change its name to Aibotics Inc., (the “Name Change”).

 

NOTE 2 - GOING CONCERN

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. To date, the Company has generated no revenues, experienced negative operating cash flows and has incurred operating losses since inception. Management expects the Company to continue to fund its operations primarily through the issuance of debt or equity.

 

For the nine months ended September 30, 2026, the Company incurred a net loss of $1,237,486, had negative cash flows from operations of $93,633 and may incur additional future losses. At September 30, 2026, the Company had total current assets of $265,266 and total current liabilities of $5,171,551 resulting in a working capital deficit of $4,906,285. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of time within one year after that date that the consolidated financial statements are issued.

 

The Company’s existence is dependent upon management’s ability to develop profitable operations. Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the Company’s efforts will be successful. No assurance can be given that management’s actions will result in profitable operations or the resolution of its liquidity problems. The accompanying consolidated financial statements do not include any adjustments that might result should the company be unable to continue as a going concern. 

 

In order to improve the Company’s liquidity, the Company’s management is actively pursuing additional equity financing through discussions with investment bankers and private investors. There can be no assurance that the Company will be successful in its effort to secure additional equity financing.

 

The financial statements do not include any adjustments relating to the recoverability of assets and the amount or classification of liabilities that might be necessary should the Company be unable to continue as a going concern.


8



NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. We believe that the disclosures contained in these condensed financial statements are adequate to make the information presented herein not misleading. These condensed financial statements should be read in conjunction with the financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC. The accompanying condensed financial statements are unaudited, but in the opinion of management contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position as of September 30, 2026, and the results of its operations and its cash flows for the three and nine months ended September 30, 2026 and 2025. The balance sheet as of December 31, 2025 is derived from the Company’s audited financial statements. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2026.

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MYC and NPD. All inter-company accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Our financial statements include, when applicable, disclosures of estimates, assumptions, uncertainties, and markets that could affect our financial statements and future operations.

 

Cash

 

The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value. The Company maintains its cash balances with a bank whose balance is insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company monitors the cash balances held in its bank accounts, and as of September 30, 2026, and December 31, 2025, did not have any concerns regarding cash balances which exceeded the insured amounts.

 

Property and Equipment, Net

 

Property and equipment are stated at cost. For financial reporting, we provide for depreciation using the straight-line method at rates based upon the estimated useful lives of the various assets. Depreciation expense was $0 and $0 for the three months ended September 30, 2026, and 2025, respectively, and $0 and $0 for the nine months ended September 30, 2026 and 2025, respectively. The Company computes depreciation utilizing estimated useful lives, as stated below:

 

Property and Equipment, Net Categories

 

Estimated Useful Life

Equipment

 

3 Years

 

Management assesses property and equipment for impairment whenever there is an indicator of impairment. Impairment losses are evaluated if the estimated undiscounted cash flows from using the assets are less than carrying value. A loss is recognized when the carrying value of an asset exceeds its fair value. Management assessed and concluded that no impairment write-down would be necessary for the Company’s property and equipment as of September 30, 2026 and December 31, 2025.

 

Finite Long-lived Intangible Assets, Net

 

Finite long-lived intangible assets are recorded at their estimated fair value at the date of acquisition. Finite long-lived intangible assets are amortized on a straight-line basis over their estimated useful lives. Management annually evaluates the estimated remaining useful


9



lives of the finite intangible assets to determine whether events or changes in circumstances warrant a revision to the remaining period of amortization.

 

Finite long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be fully recoverable. An impairment loss is recognized if the sum of the expected long-term undiscounted cash flows the asset is expected to generate is less than its carrying amount. Any write-downs are treated as permanent reductions in the carrying amount of the respective asset. Management assessed and concluded that no impairment write-down would be necessary for finite long-lived intangible assets as of September 30, 2026, and December 31, 2025.

 

The Company amortizes these intangible assets on a straight-line basis over their estimated useful lives, as stated below:  

 

Intangible Assets, Net Categories

 

Estimated Useful Life

Intellectual property

 

3 Years

 

Fair Value of Financial Instruments

 

The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures.  ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

 

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

 

Level 2 – Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data;

 

Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

 

There were no changes in the fair value hierarchy leveling during the three and nine months ended September 30, 2026 and 2025.

 

Income Taxes

 

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2026 and December 31, 2025, the Company had a full valuation allowance against its deferred tax assets.

 

We adopted ASC 740-10-25, Income Taxes—Recognition, which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10-25, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740-10-25 also provides guidance on derecognition, classification, interest and penalties on income taxes, and accounting in interim periods and requires increased disclosures. We had no material adjustments to our liabilities for unrecognized income tax benefits according to the provisions of ASC 740-10-25.

 

Stock Based Compensation

 

We follow ASC 718, Compensation–Stock Compensation, which prescribes accounting and reporting standards for all share-based payment transactions in which employee and non-employee services are acquired. Share-based payments to employees and non-employees, including grants of stock options, are recognized as compensation expense in the financial statements based on their fair values on the grant date. That expense is recognized over the period required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 


10



 

Segment Information

 

The Company operates as one operating segment with a focus on the development and management of companies and technologies that integrate artificial intelligence (AI) and robotics to enhance innovation and efficiency across multiple industries. The Company focuses on identifying, developing, and scaling businesses that benefit from automation, machine learning, and advanced robotics, driving transformative solutions in healthcare, manufacturing, logistics, and beyond. The Company’s Chief Executive Officer, as its chief operating decision maker (CODM), manages and allocates resources to the operations of the Company on a consolidated basis. The CODM assesses performance and allocates resources based on the Company’s consolidated statements of operations and key components and processes of the Company’s operations are managed centrally. Segment asset information is not used by the CODM to allocate resources. This enables our Chief Executive Officer to assess our overall level of available resources and determine how best to deploy these resources across projects to monitor and evaluate overall company performance, allocating resources, and establishing management compensation in line with our long-term company-wide strategic goals.

 

Basic and Diluted Net Loss per Share

 

Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period before giving effect to stock options, stock warrants, restricted stock units and convertible securities outstanding, which are considered to be dilutive common stock equivalents. Diluted net loss per common share is calculated based on the weighted average number of common and potentially dilutive shares outstanding during the period after giving effect to dilutive common stock equivalents. Contingently issuable shares are included in the computation of basic loss per share when issuance of the shares is no longer contingent. The common stock equivalents not included in the computation of earnings per share because the effect was antidilutive, were related to convertible debt and totaled 972,083 and 1,422,902 shares for the nine months ended September 30, 2026 and 2025, the convertible preferred stock issuable under the Philon Labs asset purchase agreement (Note 4), with a carrying value of $1,995,600 and $0 as of September 30, 2026 and 2025, and the outstanding warrants that totaled 0 shares for the nine months ended September 30, 2026 and 2025, respectively.

 

Recently Issued Accounting Standards 

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying consolidated financial statements, other than those disclosed below.

 

In November 2024, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”) and in January 2025, the FASB issued ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarified the effective date of ASU 2024-03. ASU 2024-03 will require the Company to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization, as applicable, included in certain expense captions in the Consolidated Statements of Operations, as well as qualitatively describe remaining amounts included in those captions. ASU 2024-03 will also require the Company to disclose both the amount and the Company’s definition of selling expenses. The Company will adopt ASU 2024-03 in its annual report for the year ended December 31, 2026.

 

NOTE 4 – ASSETS ACQUISITION

 

On November 28, 2023, the Company entered into an asset sale and purchase agreement with Philon Labs, LLC. (the “seller” or “Philon Labs”) for consideration of approximately $2,000,000 in exchange for the intangible assets. The purpose of the assets purchase was to begin the Company’s transition to a growth-oriented company that applies advanced engineering and design techniques to new products. The entire purchase consideration was allocated as fair value to the intellectual property acquired from the seller. The $2,000,000 was to be paid through the issuance of a new series of Preferred Stock. As of September 30, 2026, the consideration has not been issued to the seller and is recorded as shares to be issued on the consolidated balance sheet. The Company has analyzed the shares to be issued balance and determined that they are liabilities in accordance with ASC 480 – Distinguishing Liabilities from Equity. No shares were issued during the nine months ending September 30, 2026.

 


11



 

The acquired intangible assets are being amortized over their estimated useful lives of 3 years.

 

Intangible assets as of September 30, 2026 and December 31, 2025, are as follows:

 

 

September 30,

 

December 31,

 

2026

 

2025

Intellectual property

$

2,000,000 

 

$

2,000,000 

 

Less: accumulated amortization

 

(1,894,064)

 

 

(1,395,434)

 

Intangible assets, net

$

105,936 

 

$

604,566 

 

 

Amortization expense from intangible assets was $498,630 and $496,351 for the nine months ended September 30, 2026, and 2025.

 

Future amortization expense from intangible assets as of September 30, 2026, were as follows:

 

Remainder of 2026

 

$

105,936

 

Thereafter

 

 

-

 

Total remaining amortization expense

 

$

105,936

 

 

NOTE 5 – RELATED PARTY TRANSACTIONS

 

Notes Payable – Related Parties 

 

On January 30, 2024, the Company signed an agreement with a major shareholder for a $165,000 note payable. The note accrues interest at a rate of 1.75% compounded annually (Note 6 – Promissory and Convertible Notes). The note had interest expense of $2,160 and $2,159 for the nine months ended September 30, 2026 and September 30, 2025, respectively. As of September 30, 2026, the Company had recorded accrued interest of $7,705 related to the note within accrued interest on the Condensed Consolidated Balance Sheet.

 

AIBiotics Consulting Agreement with the CEO

 

On November 17, 2021, AIBiotics entered into an Executive Consulting Agreement (the “AIBiotics Consulting Agreement”), with Benjamin Kaplan (“BK”) to serve as the Company’s CEO for an initial term of 36 months. As of September 30, 2026 and December 31, 2025, the Company had cash compensation outstanding as accrued expense - related party due to the AIBiotics Consulting Agreement of $1,023,000 and $807,000, respectively. During the three and nine months ended September 30, 2026 and 2025, the Company did not recognize stock-based compensation from Warrants issued in connection with the AIBiotics Consulting Agreement. The Company records stock-based compensation on the consolidated income statement as general and administrative expense.

 

Significant terms of the AIBiotics Consulting Agreement are as follows:

 

Annual Base Consulting Fee

 

Every calendar month the Company pays the CEO a consulting fee of $24,000, with an annual total fee of $288,000.

 

Bonus Compensation Milestones

  

The Company will pay the CEO a bonus in AIBiotics restricted stock or restricted stock units based on the following EBITDA milestones. As of September 30, 2026, no EBITDA milestones were met, and no amounts have been recorded for the bonus milestones.

 

Bonus

 

 

EBITDA Milestones

$

100,000

 

 

1st $1,000,000

$

100,000

 

 

2nd $1,000,000

$

100,000

 

 

3rd $1,000,000

$

100,000

 

 

4th $1,000,000

$

100,000

 

 

5th $1,000,000

 

The Company will pay the CEO a bonus in restricted stock or restricted stock units based on the following AIBiotics market capitalization by maintaining the below market cap for AIBiotics for a period of 22 consecutive trading days:

 


12



 

 

Bonus (Shares)

 

 

Market Capitalization Milestone

 

250,000

 

 

$

30,000,000

 

250,000

 

 

$

40,000,000

 

250,000

 

 

$

60,000,000

 

250,000

 

 

$

80,000,000

 

250,000

 

 

$

100,000,000

 

 

Stock Grants – Significant Transactions

 

Upon the Company closing a Significant Transaction, the CEO shall be granted shares of AIBiotics common stock or a new series of AIBiotics preferred shares that is convertible into AIBiotics common stock equal to 5% of the value of all the consideration, including any stock, cash or debt of such completed transaction. A “Significant Transaction” shall mean a financing of at least $500,000 or the closing of an acquisition with a valuation of at least $1,000,000 for AIBiotics. As of September 30, 2026 and December 31, 2025, the Company had not granted any shares in relation to a Significant Transaction.

 

As of September 30, 2026 and December 31, 2025, there are no amounts accrued related to the bonuses.

 

Board Compensation

 

As of September 30, 2026 and December 31, 2025, the Company had accrued expenses from board compensation of $390,750 and $270,000, respectively. Accrued board compensation is included as part of Accounts payable and accrued expenses on the consolidated balance sheets.

 

NOTE 6 – PROMISSORY AND CONVERTIBLE NOTES

 

On August 27, 2021, the Company issued a lender (“Lender A”) a convertible note payable with principal of $500,000 and an original issue discount of $50,000. The note matures after 24 months and has an effective interest rate of 8%. As of September 30, 2026 and December 31, 2025, this convertible note payable was in default and therefore classified as a current liability. Default interest accrues at a rate of 20% upon default, and the default conversion price is $0.75 per share. During the year ended December 31, 2024, the Company converted $110,000 of accrued interest into 2,200,000 shares of common stock pursuant to the terms of the convertible note agreement. Although the conversion was effective as of December 31, 2024, the related shares were issued in January 2025. The fair value of the shares issued was $44,000 and was recorded within the statement of stockholders’ equity for the year ended December 31, 2025.

 

On April 22, 2025, Lender A (“the Seller”) entered into a note assignment and purchase agreement with a buyer (“Lender G”) whereas the Seller agreed to sell, assign, transfer, and convey the Note, including the unpaid principal and accrued and unpaid interest thereon to the Buyer.

 

During the year ended December 31, 2025, the Company converted $150,438 of accrued interest into shares of the Company’s common stock. Lender G received 54,079,852 common shares, with a fair value of $179,896 which is recorded within the statement of stockholder equity.

 

On April 30, 2026, Lender G assigned $50,000 of principal under an existing convertible promissory note of the Company to Lender H. In connection with the assignment, the Company issued a separate amended and restated convertible promissory note to Lender H evidencing the assigned principal amount. The note bears interest at 8% per annum, matures on April 22, 2027, and is convertible into shares of the Company's common stock at a fixed conversion price of $0.0005 per share, subject to the terms of the note. The transaction represented a transfer of existing indebtedness between lenders and did not result in any proceeds being received by the Company.

 

During the three months ended June 30, 2026, the Company converted $48,068 of the principal balance into shares of the Company’s common stock. Lender G received 96,135,676 common shares, with a fair value of $77,808, which is recorded within the statement of stockholder equity.

 

On August 26, 2026, Lender H exercised its option under the April 30, 2026 note assignment and purchase agreement to purchase $20,000 of principal under this note from Lender G. The transaction represented a transfer of existing indebtedness between lenders and did not result in any proceeds being received by the Company. On August 27, 2026, Lender H converted the $20,000 of principal into 40,000,000 shares of the Company’s common stock at a conversion price of $0.0005 per share. The shares had a fair value of $16,000 on the conversion date, and a gain on extinguishment of $4,000 was recognized.

 


13



As of September 30, 2026, the outstanding principal balance for Lender G (formerly Lender A) was $353,350 with accrued interest of approximately $47,327, for a total outstanding balance of $400,677.

 

On September 17, 2021, the Company issued a lender (“Lender B”) a convertible note payable with principal of $55,000 and an original issue discount of $5,000. The note matures after 24 months and has an effective interest rate of 8%. As of December 31, 2025, the Company had an outstanding principal amount of $55,000 due to this lender as a result of the note. On July 8, 2026, the Company issued 23,002,666 shares of common stock in full settlement of the $55,000 principal balance and $14,099 of accrued interest. The shares had a fair value of $13,802 on the issuance date, and a gain on extinguishment of $55,297 was recognized. As of September 30, 2026, no balance remains outstanding under this note.

 

On October 27, 2021, the Company issued a lender (“Lender C”) a convertible note payable with principal of $220,000 and an original issue discount of $20,000. The note matures after 24 months and has an effective interest rate of 8%. During 2025, the note was assigned to Lender G. As of September 30, 2026, and December 31, 2025, no balance remains outstanding under this note as a result of prior conversions of both principal and accrued interest completed during the year ended December 31, 2025. As of September 30, 2026, the accrued interest account related to this note had a debit balance of $33,851, which is presented as a reduction of accrued interest.

 

On January 21, 2022, the Company issued a convertible note payable to a lender (“Lender E”) with a principal balance of $325,000 and an original issue discount of $75,000. As of September 30, 2026, the outstanding principal balance was $325,000 with accrued interest of $244,202, for a total outstanding balance of $569,202. The note is currently in default and classified as a current liability. Default interest accrues at 20% per annum, and the default conversion price is $0.975 per share.

 

On January 30, 2024, the Company entered into a note payable agreement with a related party (“Lender F”) for $165,000. The note bears interest at 1.75% compounded annually. As of September 30, 2026, the outstanding principal balance was $165,000 with accrued interest of $7,705, for a total outstanding balance of $172,705.

 

On May 6, 2025, the Company issued a convertible note payable to a lender (“Lender G”) with a principal balance of $275,000 and an original issue discount of $25,000. As of September 30, 2026, the outstanding gross principal balance was $275,000 net of an unamortized debt discount of $7,466 resulting in carrying amount of $267,534. Accrued interest was $38,575 as of September 30, 2026 resulting in a total outstanding balance of $306,109. The note bears interest at 10% per annum and matures in May 2027.

 

On September 12, 2025, the Company issued a promissory note (“Lender H”) with an original principal balance of $58,823 and an original issue discount of $8,823, resulting in proceeds of $50,000. The note bears interest at 12% per annum and matured on January 2, 2026.

 

During the three months ended June 30, 2026, Lender G assigned $50,000 of principal under an existing convertible promissory note of the Company to Lender H as described above, there were principal payments of $8,409 and principal conversions of $16,711 which resulted in the issuance of 33,422,366 shares with a fair market value of $26,738 which is recorded within the statement of stockholder equity.

 

During the three months ended September 30, 2026, Lender H converted the remaining $29,880 of principal and $3,475 of accrued interest into 66,709,417 shares of common stock (37,946,617 shares on July 6, 2026 and 28,762,800 shares on July 27, 2026) at a conversion price of $0.0005 per share. The shares had a fair value of $35,191, and a loss on extinguishment of $1,837 was recognized. As of September 30, 2026, no balance remains outstanding to Lender H.

 

In March 2026, the Company entered into a convertible promissory note agreement with a lender ("Lender I"), pursuant to which it received gross proceeds of $75,000 and issued a note with a principal amount of $93,750, resulting in an original issue discount of $18,750. As of September 30, 2026, the note had an outstanding principal balance of $93,750, net of an unamortized debt discount of $13,716, resulting in a carrying value of $80,034. In addition, accrued interest totaled $5,036 as of September 30, 2026, bringing the total carrying amount of the obligation to $85,070. The note bears interest at 10% per annum and matures in March 2028.

 


14



 

The following table reflects a summary of the outstanding principal and interest by each lender and their respective maturity date as of September 30, 2026 and December 31, 2025:

 

 

 

 

 

September 30, 2026

 

December 31, 2025

 

 

Maturity Date

 

Total Outstanding***

 

Principal

 

Interest

 

Total Outstanding***

 

Principal

 

Interest

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Lender G (formerly Lender A)

 

8/27/2023

$

 400,677 

 

 353,350

 

 47,327 

 $

 471,417

 

471,417 

 

- 

Lender B

 

9/17/2023

 

 - 

 

 -

 

 - 

 

 63,403

 

55,000 

 

8,403 

Lender D

 

10/21/2023

 

 (33,851)

 

 -

 

 (33,851)

 

 2,407

 

- 

 

2,407 

Lender E

 

01/21/2024

 

 569,202 

 

 325,000

 

 244,202 

 

 515,407

 

325,000 

 

190,407 

Lender F

 

01/30/2025

 

 172,705 

 

 165,000

 

 7,705 

 

 170,546

 

165,000 

 

5,546 

Lender G

 

05/06/2027

 

 306,109 

 

 267,534

 

 38,575 

 

 266,029

 

258,185 

 

7,844 

Lender H

 

01/02/2026

 

 - 

 

 -

 

 - 

 

 10,794

 

8,667 

 

2,127 

Lender I

 

03/17/2028

 

 85,070 

*

 80,034

 

 5,036 

 

 -

 

- 

 

- 

 

 

 

 $

 1,499,912 

 

 1,190,918

 

 308,994 

 $

 1,500,003

 $

1,283,269 

 

216,734 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*** - Total Outstanding = Principal + Interest as of September 30, 2026 and December 31, 2025

 

During the nine months ended September 30, 2026 and 2025, the Company recorded debt discount amortization expense in the amount of $16,541 and $5,034, respectively. As of September 30, 2026, the Company had an unamortized debt discount balance of $21,182.

 

NOTE 7 – STOCKHOLDERS’ EQUITY

 

As of December 31, 2023, the Company was authorized to issue 5,000,000 shares of its preferred stock in one or more series, of which 1,500,000 were designated “Series B Preferred Stock”. On June 24, 2024, the Board of Directors of the Company approved the designation of one share of preferred stock as “Series A Preferred Stock”. As of September 30, 2026, the Company was authorized to issue 5,000,000 shares of preferred stock, of which 1,500,000 were designated “Series B Preferred Stock” and 1 was designated “Series A Preferred Stock”.

 

On June 24, 2024, the Board of Directors of the Company approved an increase in the authorized shares of common stock from 100,000,000 to 467,000,000. On March 19, 2025, the Company amended its Articles of Incorporation to increase the number of authorized shares from 467,000,000 to 7,500,000,000 shares. 

 

As of September 30, 2026 and December 31, 2025, the Company was authorized to issue 7,500,000,000 shares of common stock.

 

Common Stock 

 

Each share of common stock has a $0.001 par value. Each share of common stock entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought. The Company had 890,165,334 and 486,895,359 shares of common stock issued and outstanding as of September 30, 2026, and December 31, 2025, respectively.

 

For the year ended December 31, 2025, the Company issued 58,234,996 shares of common stock issued to settle $363,166 of accounts payable and accrued expenses.

 

For the year ended December 31, 2025, the Company issued 75,000,000 shares of Common stock issued to settle $225,000 accrued expenses - related party.

 

For the year ended December 31, 2025, the Company issued 16,666,667 shares of common stock in exchange for consulting services.

 

For the year ended December 31, 2025, the Company issued 297,002,793 shares of common stock issued for cash and settlement of accrued interest, net of issuance costs in the amount of $1,012,121.

 

During the three months ended March 31, 2026, the Company completed a Regulation A equity issuance pursuant to which it issued 25,572,128 shares of common stock, par value $0.001 per share, at a purchase price of $0.003 per share for aggregate proceeds of approximately $76,700. A portion of the proceeds was disbursed at closing to repay certain obligations and pay offering-related legal costs.

 


15



During the three months ended March 31, 2026, the Company issued 26,900,000 shares of common stock in connection with the conversion of $21.5 thousand of accrued interest under an outstanding convertible promissory note. The conversion was effected in accordance with the terms of the note and resulted in a reclassification of the accrued interest liability to equity, with no gain or loss recognized upon conversion.

 

During the three months ended June 30, 2026, the Company issued an aggregate of 183,139,147 shares of common stock. This included (i) 16,666,667 shares issued under a Regulation A offering in exchange for professional services with a fair value of $50,000, (ii) 129,558,042 shares issued upon the conversion of $64,779 of principal under outstanding convertible promissory notes in accordance with the terms of the respective notes, and (iii) 36,914,438 shares issued in settlement of $24,000 of outstanding accounts payable and accrued expenses. These transactions resulted in the reclassification of the related liabilities to equity, and a loss of $76,388 was recognized upon settlement.

 

During the three months ended September 30, 2026, the Company issued an aggregate of 167,658,700 shares of common stock. This included (i) 129,712,083 shares issued upon the conversion of $104,880 of principal and $18,071 of accrued interest under outstanding convertible and promissory notes in accordance with the terms of the respective notes, and (ii) 37,946,617 shares issued in settlement of $22,768 of outstanding accounts payable. These transactions resulted in the reclassification of the related liabilities to equity, and a net gain on extinguishment of liabilities of $61,753 was recognized upon settlement.

 

Series A Preferred Stock

 

As of September 30, 2026 and December 31, 2025 we were authorized to issue 1 shares of Series A Preferred Stock, $0.001 par value. The holder of the Series A Preferred is entitled to cast that number of votes on all matters presented for stockholder vote to the stockholders of the Corporation that when taking into account the votes entitled to be cast by the Series A Preferred stockholder is equal to seventy-five percent (75%) of the total shares authorized to vote on such matter(s) and such holder shall vote along with holders of the Corporation’s Common Stock on such matters. Additionally, the Series A Preferred Stock is convertible into 9,793,754 shares of Company common stock at the option of the holder.

 

Series B Preferred Stock - Mezzanine Equity

 

The Series B Preferred Stock is recorded as mezzanine equity in accordance with ASC 480, “Distinguishing Liabilities from Equity”. The Series B Shares are recorded as mezzanine equity in accordance with ASC 480 because the Company may be obligated to issue a variable number of shares at a fixed price known at inception and there is no maximum number of shares that could potentially be issued upon conversion. In this instance, cash settlement would be presumed and the Series B Shares are classified as mezzanine equity in accordance with ASC 480-10-S99. Immediately upon effectiveness of the registration statement registering for resale of all the common stock issuable under the Series B Shares, all outstanding Series B Shares shall automatically convert into common stock. As of September 30, 2026 and December 31, 2025 the Company was authorized to issue 1,500,000 shares of Series B Preferred Stock.

  

NOTE 8 - STOCK BASED COMPENSATION

 

Effective July 15, 2024, the Company adopted the AIBiotics, Inc. 2024 Equity Incentive Plan (the “2024 Plan”), which limits the number of shares that may be issued pursuant to the 2024 Plan to 50,000,000 shares of common stock. As of September 30, 2026, there have not been any stock-based compensation issuances under the 2024 Plan.

 

On January 13, 2026, the Company’s Board of Directors approved the adoption of the 2026 Equity Incentive Plan (the “Plan”), subject to stockholder approval. The Plan provides for the issuance of up to 500,000,000 shares of common stock for equity-based awards, including stock options, restricted stock, restricted stock units, and other equity or cash-based incentives, to employees, directors, consultants, and other service providers. The Plan is intended to align employee and shareholder interests and to support long-term growth and retention. During the three months ended September 30, 2026, the Company issued 37,946,617 shares of common stock registered on Form S-8 under the 2026 Plan in settlement of $22,768 of accounts payable for consulting services (see Note 7). No other awards had been granted under the 2026 Plan as of September 30, 2026.

 


16



 

Warrants Issued

 

The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the nine months ended September 30, 2026, and 2025:

 

 

 

Underlying

Shares

 

 

Weighted Average Exercise Price

 

 

Weighted Average Term (Years)

 

Warrants outstanding at December 31, 2024

 

 

166,667

 

 

$

1.50

 

 

 

0.06

 

Granted

 

 

-

 

 

 

-

 

 

 

-

 

Exercised

 

 

-

 

 

 

-

 

 

 

-

 

Forfeited/Expired

 

 

(166,667)

 

 

 

1.50

 

 

 

-

 

Warrants outstanding at September 30, 2025

 

 

-

 

 

$

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrants outstanding at December 31, 2025

 

 

-

 

 

 

-

 

 

 

-

 

Granted

 

 

-

 

 

$

-

 

 

 

-

 

Exercised

 

 

-

 

 

 

-

 

 

 

-

 

Forfeited/Expired

 

 

-

 

 

$

-

 

 

 

-

 

Warrants outstanding and exercisable at September 30, 2026

 

 

-

 

 

$ 

-

 

 

 

-

 

 

The intrinsic value of warrants outstanding as of September 30, 2026 was $0.

 

NOTE 9 – COMMITMENTS AND CONTINGENCIES

 

On November 17, 2021, the Company entered into an Executive Consulting Agreement (the “Agreement”) with Benjamin Kaplan whereby Mr. Kaplan was appointed as CEO of the Company (see Note 5 – Related Party Transactions).

 

NOTE 10 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from September 30, 2026 through the issuance date of these financial statements, and there are no events requiring disclosure except for those described below.

 

On October 2, 2026, the Company entered into an Agreement for the Exchange of Stock with Empulser Enterprises LLC, a Wyoming limited liability company (“Empulser”), and its members to acquire 100% of the membership interests of Empulser in exchange for shares of a new series of Series C Preferred Stock with an aggregate stated value of $22,000,000. Ten percent of the consideration is to be released at closing and the remainder upon Empulser achieving specified patent, product and revenue milestones within 36 months after closing; any consideration not earned is cancelled. As of the date of this report, the transaction has not closed.

 

On October 12, 2026, the Company, through NovaCore Labs Limited (“NovaCore”), a newly formed wholly owned subsidiary organized in Jamaica, acquired certain assets of PlayJamaica Limited, including software, trademarks, assigned contracts and customer data, in exchange for 22,500 shares of Series B Preferred Stock with an aggregate stated value of $225,000. The seller may earn up to $3,000,000 of additional Series B Preferred Stock upon the achievement of cumulative gross revenue milestones of $500,000, $1,500,000, $3,000,000 and $5,000,000 during the four years following the closing. The Company is evaluating the accounting for the transaction.

 

On October 12, 2026, NovaCore entered into three-year employment agreements with Gregory Moore, as Chief Executive Officer of NovaCore, and Ryan Moore, as Vice President of NovaCore. Each agreement provides for the issuance of 50,000,000 restricted shares of the Company’s common stock, vesting in equal installments on the first, second and third anniversaries of the effective date subject to continued employment; a quarterly cash bonus equal to 10% and 8%, respectively, of NovaCore’s net income, subject to a maximum of $500,000 per year; and awards of $625,000 of Series B Preferred Stock each if NovaCore achieves gross revenue of $1,000,000 from the acquired assets by the second anniversary and an additional $625,000 each if it achieves gross revenue of $2,000,000 by the third anniversary.

 

On October 16, 2026, the Board of Directors approved the issuance of 10,000,000 shares of common stock to Mark Croskery, a director, in payment of $20,000 of accrued board fees, and 100,000,000 shares of common stock to Ben Kaplan, the Company’s Chief Executive Officer, in payment of $200,000 of accrued consulting compensation, each valued at $0.002 per share based on the closing price of the Company’s common stock on October 15, 2026. Following the issuance, $823,000 of compensation due to Mr. Kaplan through September 30, 2026 remains unpaid.


17



 

On October 29, 2026, the Company issued the 10,000,000 shares of common stock to Mark Croskery and the 100,000,000 shares of common stock to Ben Kaplan approved by the Board of Directors on October 16, 2026. Following these issuances, the Company had 1,000,165,334 shares of common stock outstanding as of November 19, 2026.

 

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and the other financial information included elsewhere in this Quarterly Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report, particularly those under “Risk Factors.”

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “can,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential” and other similar words and expressions of the future.

 

Results of Operations and Financial Condition

 

Three months Ended September 30, 2026 as Compared to the three months Ended September 30, 2025

 

Sales and Cost of Sales

 

We did not have any revenue or cost of revenue from operations for the three months ended September 30, 2026 and 2025.

 

Operating Expenses

 

Operating expenses for the three months ended September 30, 2026 and 2025 consisted solely of general and administrative expenses. For the three months ended September 30, 2026, general and administrative expenses primarily included amortization expenses of approximately $168,037, CEO consulting fees of $72,000, board compensation of $48,750, meals and entertainment of approximately $5,275, legal and professional services of approximately $3,399, and stock transfer fees of approximately $1,794.

 

For the three months ended September 30, 2026, general and administrative expenses decreased by $179,037, or 37.3%, compared to the same period in 2025, decreasing from $480,364 to $301,327. The decrease was primarily attributable to a decrease in consulting fees of $130,076, a decrease in legal and professional fees of $31,736, and a decrease in advertising and marketing of $17,000, partially offset by an increase in board compensation of $8,750.

 

Other Expense

 

For the three months ended September 30, 2026, other income (expense), net changed by $68,471 compared to the same period in 2025, from other expense of $49,557 to other income of $18,914. The change was primarily driven by a net gain on extinguishment of liabilities of $61,753 on the settlement of convertible notes, accounts payable, accrued expenses and services through the issuance of common stock during the quarter and the absence of the $38,403 loss on extinguishment recognized in the prior-year period, partially offset by higher interest expense of $31,685

 

Net Loss

 

For the three months ended September 30, 2026 and 2025 we had a net loss of $282,413 and $529,921, respectively.


18



Nine months Ended September 30, 2026 as Compared to the Nine months Ended September 30, 2025

 

Sales and Cost of Sales

 

For the nine months ended September 30, 2026, we had revenue and cost of revenue from operations of $0, as compared to $2,183 in revenue and $0 in cost of revenue from operations for the nine months ended September 30, 2025.

 

Operating Expenses 

 

Operating expenses for the nine months ended September 30, 2026 and 2025 consisted solely of general and administrative expenses. For the nine months ended September 30, 2026, general and administrative expenses primarily included amortization expenses of approximately $498,630, board compensation of $137,500, consulting fees of approximately $95,041, CEO consulting fees of $144,000, software development expense of approximately $56,950 and legal and professional services of approximately $83,848.

 

For the nine months ended September 30, 2026, general and administrative expenses decreased by $298,137, or 21.7%, compared to the same period in 2025, decreasing from $1,372,590 to $1,074,453. The decrease was primarily attributable to a decrease in consulting fees of $167,720, a decrease in product development expenses of $156,372, and a decrease in legal and professional fees of $32,523, partially offset by an increase in software development fees of $56,535 and an increase in board compensation of $17,500.

 

Other Expense

 

Other expense for the nine months ended September 30, 2026 decreased by $74,027, or 31.2%, compared to the same period in 2025, decreasing from $237,060 to $163,033. The decrease was primarily attributable to a lower net loss on extinguishment of liabilities of $14,635 in 2026 (a $76,388 loss in the second quarter partially offset by a $61,753 gain in the third quarter) compared to a loss on extinguishment of $70,713 in 2025, and lower interest expense of $17,949.

 

Net Loss

 

For the nine months ended September 30, 2026 and 2025 we had a net loss of $1,237,486 and $1,607,467, respectively.

 

Liquidity and Capital Resources

 

Liquidity is the ability of an enterprise to generate adequate amounts of cash to meet its needs for cash requirements. As of September 30, 2026, we had $223,074 in cash and cash equivalents compared to $255,940 at December 31, 2025, a decrease of $32,866 resulting primarily from cash used in our operations. As of September 30, 2026, we had undiscounted obligations in the amount of approximately $1.5 million, including accrued interest, relating to the payment of indebtedness due within one year.

 

As of September 30, 2026, we had a working capital deficiency of $4,906,285 up from a working capital deficiency of $4,564,798 as of December 31, 2025. At September 30, 2026 our current assets were $265,266 and consisted primarily of cash. At September 30, 2026 our current liabilities were $5,171,551 and consisted predominantly of accounts payable and accrued expenses, related party accrued expenses, convertible notes payable, and shares to be issued. We had an accumulated deficit of $14,262,493 as of September 30, 2026, an increase from an accumulated deficit of $13,025,007 as of December 31, 2025. We plan to fund our operations with our cash on hand and additional financing.

 

Cash Flows

 

 

 

Nine months Ended September 30,

 

 

 

2026

 

 

2025

 

Net cash used in operating activities

 

$

(93,633)

 

 

$

(371,636)

 

Net cash provided by investing activities

 

 

- 

 

 

 

- 

 

Net cash provided by financing activities

 

 

60,767 

 

 

 

417,009 

 

Net increase (decrease) in cash

 

$

(32,866)

 

 

$

45,373 

 

 

Operating activities used net cash of $93,633 for the nine months ended September 30, 2026, as compared to using net cash of $371,636 for the nine months ended September 30, 2025. For the nine months ended September 30, 2026, cash used in operating activities was primarily driven by our net loss of $1,237,486; offset primarily by non-cash additions of amortization expense of $498,630, amortization of debt discount of $16,541, issuance of common stock for services of $50,000, and a non-cash loss on extinguishment of liabilities of $14,635, and changes in operating assets and liabilities including the increase in accounts payable and accrued expenses of $266,059, the increase in related party accrued expenses of $216,000, the increase in accrued interest of $110,013, the decrease in prepaid expenses


19



of $12,500, partially offset by the increase in inventory of $40,525. For the nine months ended September 30, 2025, cash used in operating activities was primarily driven by our net loss of $1,607,467; offset primarily by non-cash adjustments for amortization expense of $496,351, the loss recognized on common stock issued to settle liabilities of $70,713 and amortization of debt discount of $5,034, and changes in operating assets and liabilities including the increase in accounts payable and accrued expenses of $484,935, the increase in related party accrued expenses of $126,000, and the increase in accrued interest of $52,798.

 

Investing activities used net cash of $0 for the nine months ended September 30, 2026, and 2025.

 

Financing activities produced cash flows of $60,767 and $417,009 for the nine months ended September 30, 2026, and 2025, respectively. For the nine months ended September 30, 2026, financing activities were composed primarily of proceeds from convertible notes payable of $98,000 offset by $37,233 of the repayment of convertible notes payable.  For the nine months ended September 30, 2025, financing activities were composed of proceeds from convertible notes payable of $250,000 and proceeds from the issuance of common stock of $167,009.

 

Going Concern

 

Our consolidated financial statements have been prepared assuming we will continue as a going concern. Our ability to continue our operations as a going concern is dependent on management’s plans. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should we be unable to continue as a going concern.

 

For the nine months ended September 30, 2026, the Company incurred a net loss of $1,237,486, had negative cash flows from operations of $93,633 and may incur additional future losses. At September 30, 2026, the Company had total current assets of $265,266 and total current liabilities of $5,171,551, resulting in a working capital deficit of $4,906,285. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of time within one year after that date that the consolidated financial statements are issued.

 

The Company’s existence is dependent upon our ability to develop profitable operations. We are devoting substantially all of our efforts to developing the Company’s business and raising capital and there can be no assurance that our efforts will be successful. No assurance can be given that our actions will result in profitable operations or the resolution of its liquidity problems. The accompanying consolidated financial statements do not include any adjustments that might result should the company be unable to continue as a going concern. 

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Critical Accounting Policies

 

We have identified the policies outlined below as critical to our business operations and an understanding of our results of operations. The list is not intended to be a comprehensive list of all of our accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by generally accepted accounting principles in the United States, with no need for management’s judgment in their application. The impact and any associated risks related to these policies on our business operations is discussed throughout Management’s Discussion and Analysis of Financial Condition and Results of Operations when such policies affect our reported and expected financial results. For a detailed discussion on the application of these and other accounting policies, see the notes to our September 30, 2026, financial statements. Note that our preparation of the financial statements requires us to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities at the date of our financial statements, and the reported amounts of revenue and expenses during the reporting period. We cannot assure that actual results will not differ from those estimates.

 

Intangible assets, net

 

The Company’s intangible assets include finite lived assets. Finite lived intangible assets, consisting of intellectual property are amortized on a straight-line basis over the estimated useful lives of the assets.

 

Finite lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. An impairment loss is recognized if the sum of the expected long-term undiscounted cash flows the asset is expected to generate is less than its carrying amount. Actual future cash flows may differ from the estimates used in the impairment testing.


20



Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from those estimates. The Company’s estimates include the useful lives of property plant and equipment.

 

The depreciation of equipment is dependent upon estimates of useful lives and residual values, both of which are determined through the exercise of judgement. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that consider factors such as economic/market conditions and the useful lives of assets. 

 

Stock Based Compensation

 

We follow ASC Topic 718, Compensation–Stock Compensation, which prescribes accounting and reporting standards for all share-based payment transactions in which employee and non-employee services are acquired. Share-based payments to employees and non-employees, including grants of stock options, are recognized as compensation expense in the financial statements based on their fair values on the grant date. That expense is recognized over the period required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

Recently Issued Accounting Pronouncements

 

We are subject to recently issued accounting standards, accounting guidance and disclosure requirements. For a description of these new accounting standards, see Note 3, “Summary of Significant Accounting Policies,” of the Notes to our Unaudited Condensed Consolidated Financial Statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not Applicable.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Principal Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As a result of a material weakness in our internal control over financial reporting, our Chief Executive Officer and Principal Accounting Officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of September 30, 2026.


21



PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

None.

 

Item 1A. Risk Factors.

Not required for smaller reporting companies.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Unregistered Sales of Equity Securities  

 

During the three months ended September 30, 2026, the Company issued an aggregate of 129,712,083 shares of common stock upon the conversion of $104,880 of principal and $18,071 of accrued interest under outstanding convertible and promissory notes, as described in Note 6 and Note 7 to the condensed consolidated financial statements. The shares were issued in reliance on exemptions from registration under the Securities Act of 1933, as amended, including Section 3(a)(9) and Section 4(a)(2) thereof.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None

 

Item 6. Exhibits

 

Exhibit

Number

 

 

Description

 

 

 

31.01

 

Certification of Principal Executive and Principal Financial Officer Pursuant to Rule 13a-14

 

32.1

 

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 


22



SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

AIBiotics Therapies, Inc.

 

 

Date: November 20, 2026

By:

/s/ Ben Kaplan

 

Name: 

Ben Kaplan

 

Title:

Chief Executive Officer and Principal Accounting Officer


23

Keep reading